Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung


  • Barbara Ziemba - , Lodz University of Technology (Autor:in)
  • Ida Franiak-Pietryga - , Lab Clin & Transplant Immunol & Genet (Autor:in)
  • Marjorie Pion - , Hospital General Universitario Gregorio Marañon (Autor:in)
  • Dietmar Appelhans - , Leibniz Institute of Polymer Research Dresden (Autor:in)
  • Maria Angeles Munoz-Fernandez - , Hospital General Universitario Gregorio Marañon, CIBER - Centro de Investigación Biomédica en Red (Autor:in)
  • Brigitte Voit - , Leibniz Institute of Polymer Research Dresden (Autor:in)
  • Maria Bryszewska - , Lodz University of Technology (Autor:in)
  • Barbara Klajnert-Maculewicz - , Lodz University of Technology (Autor:in)


Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers' desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) - for full (dense shell - DS) or partial (open shell - OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications of cancer nanotechnology, therefore a partial modification of the surface appears to be a perfect solution for this purpose. (C) 2013 Elsevier By. All rights reserved.


Seiten (von - bis)391-402
FachzeitschriftInternational Journal of Pharmaceutics
PublikationsstatusVeröffentlicht - 30 Jan. 2014
Extern publiziertJa

Externe IDs

PubMed 24361266
Scopus 84891596676
ORCID /0000-0002-4531-691X/work/148607911


Ziele für nachhaltige Entwicklung


  • Apoptosis, Dendrimer, Glycodendrimer, Ppi, Proliferation, Toxicity